Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

UK Bans Super-Sized Chocolate Bars from Hospital Shops

Published: Tue, 17 Oct 2017 12:36:11 EDT
Hospital shops are to be banned from stocking 'super-sized' chocolate bars by NHS England.
WebMD Health News

Jamie Oliver's Sugary Drinks Levy 'Cut Sales'

Published: Tue, 17 Oct 2017 12:20:45 EDT
A 'sugar tax' imposed on sugar-sweetened drinks in a UK restaurant chain led to a fall in sales and more people choosing healthier alternatives, an investigation has found.
WebMD Health News

Stroke, Cardiac Events Increased After First Stroke in Young

Published: Tue, 17 Oct 2017 11:59:54 EDT
As in older patients, the risk for recurrent stroke after an index stroke is increased in patients aged 18 to 45 years, along with the risk for cardiac events, a new study shows.
Medscape Medical News

FDA Eyes Weekly Semaglutide for Diabetes as Oral Version Advances

Published: Tue, 17 Oct 2017 11:12:55 EDT
An FDA advisory panel will address a possible retinopathy risk with the investigational once-weekly injectable GLP-1 agonist for type 2 diabetes, while an oral formulation has succeeded in a phase 2 trial.
Medscape Medical News
Displaying results 5-8 (of 20)
 1 - 2 - 3 - 4 - 5 


Biotech builder Cydan gets cash injection for genetic disorders

Published: Tue, 17 Oct 2017 09:04:03 +0000
Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund. The company, which has spun out several biotechs, is looking to repeat its successes by using the cash boost to seek out preclinical rare disease candidates.

Pfizer’s son of Xalkori impresses in phase 2 NSCLC trial

Published: Mon, 16 Oct 2017 13:33:38 +0000
Pfizer has posted a full look at data from a phase 2 trial of lorlatinib in patients with advanced non-small cell lung cancer (NSCLC). The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment pathways.

A big step forward in linking the genome to disease risk

Published: Mon, 16 Oct 2017 13:21:19 +0000
The human genome was first mapped about 15 years ago, but scientists have yet to gain a complete understanding of how genes govern the emergence of certain diseases. Now, a team of researchers led by Princeton University has taken a big step towards reaching that goal, publishing data related to 44 different human tissue types.

Ionis digs into phase 3 data ahead of Alnylam showdown

Published: Mon, 16 Oct 2017 12:35:27 +0000
Ionis Pharmaceuticals has shared a closer look at phase 3 data on inotersen in patients with hereditary TTR amyloidosis. The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam.
Displaying results 5-8 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy